Cancer-cell targeting in preclinical research
1Scope of investigation or explicitly identified community interest; not an established indication.
Immune
PNC-27
An experimental anticancer peptide
Lab studiesCancer-cell targeting1
Investigational; this profile does not establish an approved use.
What does it do?
An experimental p53-derived anticancer peptide; laboratory tumor-cell effects do not establish cancer treatment in people.
Approved & studied uses
Evidence limits
View research →No verified human oncology trial establishes benefit, dosing or systemic safety.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Systemic selectivity unknown
Sparing one normal-cell line does not establish safety of normal organs during human exposure.1
Investigational; this profile does not establish an approved use.
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed12
Length32 amino acids
Molecular weight · Da4031.72 Da
Formula, sequence notation & identity
p53-derived HDM-2-binding segment joined to a membrane-penetrating segment
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
32 amino acids · 4031.72 Da
Reference description; checked chemical identity above takes precedence when available.12
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman kinetics not established1
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Scope of evidence
No verified human oncology trial establishes benefit, dosing or systemic safety.1
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Effectiveness
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Experience
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “68 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Reported selectivity does not establish whole-body safety.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubQ (abdomen) | 100-500 mcg | Once daily, subcutaneous | Standard Research ProtocolReference report | 8-12 weeks (community protocol, not clinically validated) | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Reported selectivity does not establish whole-body safety. Source tabs Injectable | |||||
| SubQ | 100 mcgStarting dose | Once daily, subcutaneous | Starting/Conservative DoseReference report | 8-12 weeks (community protocol, not clinically validated) | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Reported selectivity does not establish whole-body safety. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 8-12 weeks (community protocol, not clinically validated)
- Break
- No established protocol — insufficient data
Reported timing
Morning or evening, consistent timing daily
Side effects & safety
Systemic selectivity unknown
Sparing one normal-cell line does not establish safety of normal organs during human exposure.
1Cancer treatment gap
No verified human trial establishes cancer benefit, survival improvement or a safe systemic regimen.
1Critical
No verified human efficacy/safety trials. Never substitute for oncology treatment.
Product risk
FDA detected bacterial contamination in a marketed PNC-27 sample.
Stop symptoms
Fever/chills, infected sites, allergy, systemic illness or worsening cancer symptoms require medical assessment.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Paclitaxel
Unverified pairingEx-vivo findings only.12
Reference report · Pep-Pedia label: SynergisticKetone bodies
Unverified pairingCell-culture findings only.12
Reference report · Pep-Pedia label: SynergisticThymosin Alpha-1
Unverified pairingNo combination evidence.12
Reference report · Evidence context: UnknownOther chemotherapy
Unverified pairingNot established by paclitaxel findings.12
Reference report · Evidence context: UnknownCheckpoint inhibitors
Unverified pairingSpeculative immune effects.12
Reference report · Evidence context: UnknownHDM-2 inhibitors
Unverified pairingUnstudied pairing.12
Reference report · Evidence context: UnknownBPC-157 / TB-500
Unverified pairingUnstudied pairing.12
Reference report · Evidence context: UnknownOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 28 days.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported variationFDA Warning IssuedReported variationNo Verified Human TrialsReported appearanceThird-Party Testing RequiredReported appearanceLyophilized Powder FormReported concernNebulized/Inhalable ProductsReported concernCure Claims
12Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.12
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalSource context
Reported selectivity does not establish whole-body safety.
Compound identity & other names
PNC-27 targets membrane-associated HDM-2 in experimental cancer models. Laboratory selectivity is not a demonstrated cancer treatment or proof that normal organs are protected during systemic exposure.
Other names: PNC27
Investigational; this profile does not establish an approved use.
How it may work
Targets membrane HDM-2 and disrupts membranes; mitochondrial effects are also investigated.12
Cervical cancer cells in culture
The study tested HTB-35/SiHa and a normal cervical-cell line. Its reported 12.4 μM IC50 is a cell-culture concentration, not a human dose.
1Source checks & newer research
FDA: Unproven products marketed for cancer
FDA identifies a January 2017 PNC-27 sample contaminated with Variovorax paradoxus; this is a specific product finding, not an incidence estimate for all products.
Regulatory safety notice13Research areas and evidence gaps
Cancer-cell targeting in preclinical research. Scope of investigation or explicitly identified community interest; not an established indication.1
- No verified human oncology trial establishes benefit, dosing or systemic safety.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
The targeted newer-literature check did not identify an additional verified exact-compound clinical outcome study beyond the retained evidence. This is not a systematic-review conclusion.
- Checked
- 2026-10-12
- Search
- PNC-27 2025 2026 study
- Catalog
- Pep-Pedia ↗ · 10 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical CellsAbstract checked
AI-PREPARED SUMMARY
Cultured cervical-cancer cells were killed under laboratory conditions while a tested normal-cell line was spared.
Cervical cancer cells in culture
The study tested HTB-35/SiHa and a normal cervical-cell line. Its reported 12.4 μM IC50 is a cell-culture concentration, not a human dose.
Pep-Pedia bibliography · Checked 2026-10-12
2Pep-Pedia: PNC-27Community source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Sarafraz-Yazdi E, Mumin S, Engel D, et al. (2010). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cancer-cell assays showed membrane pores and cell death with relative sparing of tested fibroblasts; no patient anticancer efficacy was established.
Reported population / model
MIA-PaCa-2, MCF-7, A-2058 cells
Reported study details
IC50 ~33 μM · 90 min to 100% kill
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Sarafraz-Yazdi E, Bowne WB, Engel D, et al. (2010). The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Only the linked two-domain peptide disrupted cancer-cell membranes; separate or unlinked domains did not reproduce the effect.
Reported population / model
Cancer cell lines
Reported study details
Structure-activity relationship · Covalent linkage required
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Leukemia Cell Selective Necrosis (2014)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Several leukemia-cell lines underwent necrotic death in culture while tested normal lymphocytes were spared.
Reported population / model
K562, U937, HL60 cells
Reported study details
IC50 4.7-91.1 μM · No effect on normal lymphocytes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Kanovsky M, Raffo A, Drew L, et al. (2015). Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer. Annals of Clinical & Laboratory Science.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Patient-derived ovarian/endometrial cells responded outside the body, with an experimental paclitaxel interaction; this was not treatment of patients.
Reported population / model
Patient-derived cells
Reported study details
Ovarian LD50 100 μg/mL · Paclitaxel synergy
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Sarafraz-Yazdi E, et al. (2020). Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. Anticancer Research.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Laboratory leukemia selectivity and animal blood-count observations were reported; these do not establish human cancer safety or effectiveness.
Reported population / model
Leukemia cells vs normal hematopoietic/stem cells
Reported study details
In vivo safety
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pincus MR, Sarafraz-Yazdi E, et al. (2024). Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical & Laboratory Science.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes mitochondrial as well as plasma-membrane disruption in cancer cells, with lysosomes relatively spared.
Reported population / model
Cancer cells
Reported study details
Plasma membrane + mitochondrial targeting · Lysosome sparing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Sarafraz-Yazdi E, Fridman D, Lin B, et al. (2022). PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Sarafraz-Yazdi E, Mumin S, Engel D, et al. (2010). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Sarafraz-Yazdi E, Fridman D, Lin B, et al. (2022). PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Pep-Pedia: PNC-27 — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
13FDA: Unproven products marketed for cancerPrimary source checked
AI-PREPARED SUMMARY
FDA identifies a January 2017 PNC-27 sample contaminated with Variovorax paradoxus; this is a specific product finding, not an incidence estimate for all products.
FDA: Unproven products marketed for cancer
FDA identifies a January 2017 PNC-27 sample contaminated with Variovorax paradoxus; this is a specific product finding, not an incidence estimate for all products.
Additional primary-source check · Checked 2026-10-12